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Abstract
Significant levels of circulating immune complexes (ICs)
containing rheumatoid factors and immunoglobulin G in
peripheral blood are a characteristic feature of rheumatoid
arthritis (RA). ICs interact through Fcγ receptors (FcγR) to
activate phagocytes in numerous inflammatory processes. The
high concentration of neutrophils in synovial fluid during active
phases of the disease, together with their destructive capacity,
pose important questions as to their role in the pathogenesis of
RA. Functional defects in RA or control peripheral blood
neutrophil FcγRs were examined with a specific FcγR-mediated
reactive oxygen species (ROS) assay. Heterologous cross-
linking of FcγRIIa and FcγRIIIb on neutrophils resulted in a
significantly decreased production of ROS by RA cells
compared with controls matched for age and sex. However,
expression and homologous ligation of receptors did not differ
between these groups. These data suggest that neutrophil
priming does occur before emigration into the joint and that
blood neutrophils from patients with RA have a functional
impairment in cooperative FcγR-mediated ROS generation. This
may account for the increased susceptibility to bacterial
infection that arises in patients with severe disease.
Introduction
Immune complex (IC) formation is a characteristic feature of
rheumatoid arthritis (RA). ICs have been located in the synovial
fluid, the superficial layers of the cartilage and circulating in the
periphery [1-3]. ICs activate inflammatory processes by two
main overlapping mechanisms: first, through the soluble pro-
teins of the complement system, and second, through interac-
tion with one of three described receptors for the Fc constant
region of immunoglobulin G (IgG), the Fcγ receptors (FcγR)
[3-5]. IC interaction through FcγRs activates phagocytic neu-
trophils and mononuclear phagocytes in several inflammatory
processes.
Both murine and human studies have provided evidence for a
primary role of neutrophils in RA. Of the cells infiltrating the
synovial fluid during the active phases of RA, 80 to 90% are
neutrophils and turnover can exceed 109 cells per day in a 30
ml joint effusion [6,7]. Depletion of neutrophils in an experi-
mental model of the disease prevents the development of
inflammation and decreases it once it has ensued [8]. Activa-
tion of neutrophils leads to degranulation, phagocytosis and
the generation of reactive oxygen species (ROS) [9,10]. The
subsequent release of proteolytic enzymes and reactive oxy-
gen metabolites can result in tissue damage [11,12].
Neutrophils express FcγRIIa (CD32a), which is a single-trans-
membrane receptor with its own immunoreceptor tyrosine-
based activation motif (ITAM) in the intracellular domain, and
FcγRIIIb (CD16b), which does not have a cytoplasmic tail but
is inserted into the membrane by means of a
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glycosylphosphatidylinositol anchor [13,14]. This FcγRIII iso-
type is expressed exclusively on granulocytes. It is the most
abundant FcγR present on neutrophils and it believed to be the
primary binding molecule for ICs, working in tandem with
FcγRIIa or complement receptor type 3(CR3; also referred to
as CD11b/CD18 or Mac-1) to mediate a full inflammatory
response. Despite the lack of an intracellular signalling
domain, homotypic ligation may transduce signalling events
that are distinct from homotypic FcγRIIa and heterologous liga-
tion [15].
In addition, there is a large amount of evidence that FcγRIIIb is
important in both IC-mediated activation and phagocytosis of
opsonised bacteria. Several investigations have shown that
inhibition or removal of this receptor restricts both insoluble
and soluble IC-mediated activation [16-20]. However, the
extent of FcγRIIIb involvement is subject to debate.
Allelic specificity of FcγRIIIb affects the efficiency of phagocy-
tosis of opsonised bacteria [21,22]. FcγRIIIb exists as one of
three serological allotypes: neutrophil antigen (NA)1, NA2 or
SH-FcγRIIIb (also referred to as HNA-1a, HNA-1b and HNA-
1c, respectively [23], in which NA1 and NA2 differ in five
nucleotides and SH-FcγRIIIb differs from NA2 at a single base.
FcRγIIIb-NA1 has been shown to mediate a higher response in
the internalisation of erythrocytes, as well as in the phagocyto-
sis of opsonised bacteria. There have been no significant
associations between polymorphisms in FcγRIIIb and the
development of disease; however, patients with RA who have
the NA2 allele are associated with an increased prevalence of
respiratory tract infections [24-27]. This suggests a mechanis-
tic role for FcγRIIIb in the well-known increased susceptibility
and increased risk of death from bacterial infection observed
in RA [28-30].
The importance of the adhesion molecules, integrins and
selectins in mediating the rolling and tethering of neutrophils
to the endothelium is well established [31]. In this study we
measured the expression of L-selectin (CD62L) and β-integrin,
CR3, which are established markers of neutrophil activation
[32,33]. The most accepted inflammatory measurements used
in clinical medicine are the erythrocyte sedimentation rate
(ESR) and levels of C-polysaccharide reactive protein (C-reac-
tive protein; CRP) [34]. ESR indirectly reflects potentially
increasing serum proteins, such as fibrinogen, acute-phase
proteins and immunoglobulins [35]. CRP is the most studied
acute-phase protein and is a good measure of activity of dis-
ease because high circulating levels are correlated with the
acute inflammatory stages of the disease, and low levels with
quiescent stages [36].
The destructive capacity of joint neutrophils in RA, together
with a delay in apoptosis, is well established, but peripheral
changes in neutrophil function are less clear. In this study we
examined the expression and function of the individual FcγRs
on neutrophils in patients with RA who had active synovitis.
Although the basal and stimulated expression of FcγRIIa was
similar to that of FcγRIIIb, heterologous ligation of both recep-
tors resulted in a decrease in FcγR-mediated ROS generation
in patients with RA. Although several studies have demon-
strated that individual homologous or heterologous ligation of
FcγRIIa and FcγRIIIb may induce ROS generation, this is the
first report to demonstrate a deficiency in the co-ligation of
these receptors in RA [17,37,38].
Materials and methods
Patients
Patients attending the Rheumatology Clinic at The Royal Lon-
don Hospital, Mile End, London, UK, were diagnosed with RA
ac the criteria outlined by the American College of Rheumatol-
ogy (ACR (ARA) [39]). Of 18 patients with RA recruited for the
investigations, 4 were male and 14 were female. Demograph-
ics of the patients are shown in Table 1. All were assessed as
having active synovitis. Peripheral blood was collected into a
syringe Vacutainer containing 3.8% EDTA (10% v/v; Becton
Dickinson, Oxford, UK). The average age of all 36 volunteers
was 62.6 ± 13.2 (mean ± SD). Venous blood samples from
control volunteers matched for age and sex were taken within
1 hour of collection from the patient. All blood was taken with
full consent and with prior approval from the local research
ethics committee (East London and City Health Authority Eth-
ics Committee). Circulating blood levels of haemoglobin,
CRP, leucocytes and platelet counts, in addition to the ESR,
were determined in the population with RA at the hospital
where they were receiving treatment.
Isolation of leucocytes by dextran sedimentation
Preliminary studies demonstrated that the surface expressions
of L-selectin and CR3 were altered on cell separation by using
density centrifugation methods (Percoll and Ficoll; data not
shown). Dextran sedimentation produced minimal phenotypic
cellular changes and controlled for serum immunoglobulin and
differences in cell numbers. The expression of FcγRs was unal-
tered, regardless of cell separation procedure. Receptor
expression was analysed in isolated leucocytes from anticoag-
ulated peripheral blood by dextran sedimentation. Blood was
mixed 1:1 with prewarmed 2% dextran (Polysciences Inc.,
Warrington, PA, USA) in RPMI medium (Sigma, Poole, UK)
and incubated at 37°C for 30 minutes to sediment the eryth-
rocytes preferentially. The white-cell supernatant was removed
and centrifuged at 1,400 r.p.m. for 5 minutes; the cell pellet
was washed in 1% BSA in PBS (prechilled to 4°C). The cell
pellet was resuspended with staining buffer (prechilled to 4°C)
to a concentration of 5 × 106 cells/ml. All subsequent staining
procedures were conducted on ice.
In vitro stimulation of leucocytes with fMet-Leu-Phe or 
tumour necrosis factor
Blood was incubated 1:1 with RPMI complete medium, com-
prising RPMI 1640, 10% heat-inactivated fetal bovine serumAvailable online http://arthritis-research.com/content/9/2/R29
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(FBS), 0.1 ml of sodium pyruvate, 2.0 mM L-glutamine, 25 mM
1 M HEPES, 0.1 mM non-essential amino acids, 0.25 μg/ml
amphotericin, 50 μg/ml gentamicin and 50 μM 2-mercap-
toethanol (all from Sigma) with or without pre-optimised con-
centrations of fMet-Leu-Phe (fMLP) (final concentration 100
nM) or TNF-α (100 U/ml; 10 ng/ml) for 0 minutes, 30 minutes,
1 hour or 4 hours at 37°C. After incubation, white blood cells
were separated by the dextran sedimentation method
described above and resuspended to 5 × 107cells/ml for
extracellular staining of the cells.
Monoclonal antibodies
Murine monoclonal antibodies with the following specificities
were used for primary stage staining: anti-FcγRIII (3g8), anti-
FcγRII (iv.3), anti-NA1-FcRIIIb (CLBgran11) and anti-NA2-
FcRIIIb (GRM1); all were gifts from Dr Paul Guyre (Dartmouth
College, Hanover, NH, USA). CD62L and CD11b were pur-
chased from Serotec (Oxford, UK). Secondary goat anti-
mouse IgG F(ab')2 conjugated with fluorescein isothiocyanate
was from CALTAG Labs (Burlingame, CA, USA).
Staining procedure
Leucocytes were pipetted into a 96-well polypropylene plate
(Costar, Cambridge, MA, USA) at a concentration of 250,000
per well. The plate was centrifuged (1,400 r.p.m. for 5 minutes
at 4°C) and the supernatant was aspirated. The cells and rea-
gents were kept at 4 to 8°C for the remainder of the experi-
ment. To the cell pellet, blocking IgG (12 mg/ml Cohn Fraction
II/III; Sigma) and specific primary antibody at 60 μg/ml were
added and incubated for 45 minutes on ice. The cells were
washed three times in staining buffer consisting of 0.2% BSA
and 1 μg/ml sodium azide in PBS. The goat F(ab')2 anti-mouse
Table 1
RA patient demographic data, blood inflammatory parameters and treatment profile
Sex Age ESR
(mm/h)
CRP
(mg/l)
Hb
(g/dl)
Platelets
(× 109/l)
WBC
(× 109/l)
Lymphocytes
Neutrophils (× 109/l) (× 109/)
Medication
M 71 58 60 12.7 351 10.3 7.8 1.7 Diclofenac
M 53 93 36 10.3 417 10.5 8.4 1.5 Methotrexate
M 78 57 74 12.4 422 7.8 5.5 1.5 -
M 62 16 17 14.1 207 6.1 3.5 2 -
F 61 37 - 12.3 261 6.1 3.9 1.6 Leflunomide
F 75 61 77 11.6 246 6.5 5.3 0.8 -
F 42 27 17 13.7 356 12.7 10.4 1.8 -
F 63 49 45 11.1 359 5.8 4.7 0.6 Clarithromycin
F 56 20 - 13.9 263 8 5 2.5 Methotrexate, prednisolone, Losec, perindopril, 
Sinemet, aspirin
F 82 37 - 12 195 8.2 5.6 1.8 -
F 63 41 41 11.4 309 9.8 9.6 3.3 -
F 57 - 13.9 - - - - - Methotrexate, prednisolone, (depo-medrone)
F 76 57 72 11 244 7.7 6.3 0.9 -
F 49 - - 11.4 204 7.2 4.4 2.5 Azothioprine, meloxicam
F 45 48 - 12.9 259 7.4 5.6 1.3 Methotrexate, indomethacin
F 92 1 - 13.9 232 9.6 7.5 0.9 Penicillamine
F 56 18 - 13.7 481 8.2 5.1 1.9 Methotrexate, folic acid, prednisolone, Vioxx, 
antihypertensive treatment
F 44 7 - 13.2 241 7.1 4.8 1.3 Leflunomide
F 68 12 5 12.7 284 6.9 4.6 1.7 Azothioprine, prednisolone, alendronate, 
thyroxine, Losec
F 56 18 23 13.7 481 8.2 5.1 1.9 -
F7 8 1 2 5 - - - - - -
F5 2 1 6 1 1 - - - - - L e f l u n o m i d e
Eighteen patients (4 male, 14 female; age 62.6 ± 13.4 years (mean ± SD) with active synovitis and receiving a range of disease-modifying anti-
rheumatic agents were recruited into the study. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Hb, haemoglobin; WBC, white 
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IgG fluorescein isothiocyanate conjugate was then added, at
1 μg per well, for 30 minutes on ice. The cells were washed
with staining buffer and the remaining erythrocytes were lysed;
the leucocytes were fixed with BD Fix and Lyse reagent (Bec-
ton Dickinson). The cells were then washed twice more in
staining buffer, resuspended to 200 μl in 1% paraformalde-
hyde and maintained at 4°C in the dark until analysis.
Analysis of changes in antigen expression
Analysis by flow cytometry was performed with either a FAC-
SCalibur or a FacScan analyser (Becton Dickinson). Forward
and side-scatter gating removed contaminants such as cell
debris. Data were acquired and analysed with the CellQuest®
application on a Power Macintosh G3 computer. Analysis of
leucocyte subpopulations was completed with forward and
side-scatter analysis. Monocytes were found to have high
CD14 expression, neutrophils had low CD14 expression and
lymphocytes were negative for CD14 expression. Expression
of the receptors was correlated with the clinical measure-
ments of disease made in the clinic, such as CRP, ESR and
cell numbers. For each sample a minimum of 2,000 monocytes
in the mixed leucocyte population were collected. The individ-
ual cell populations were then gated according to cell type and
the specific median fluorescence intensity for each receptor
was evaluated. Calibration was completed with Rainbow
Microspheres (Sphereotech, Libertyville, IL, USA) to maintain
consistency between experiments and to remove background
fluorescence. Final values were expressed as milliequivalents
of soluble fluorescein [40].
Quantification and viability of leucocytes
Türk's solution, comprising 0.01% crystal violet in 3% acetic
acid (Sigma), was prepared in distilled water and used for the
enumeration of leucocytes. Trypan blue solution was used to
determine the percentage of viable cells. Cells were resus-
pended in PBS, diluted 1:10 in trypan blue (0.4%; Sigma) and
examined with a haemocytometer within 5 minutes of the addi-
tion of the dye. In addition to trypan blue staining, the apoptotic
state of cells was assessed by the determination of hypodip-
loid DNA, because DNA breakdown is a hallmark of apoptosis.
This was completed with propidium iodide as described previ-
ously [41]. In brief, cells were resuspended in 300 μl of PBS
in 2% FBS (BioWhittaker, Walkersville, MD, USA) and perme-
abilised with 750 μl of ice-cold ethanol for 10 minutes at 4°C
(BDH Laboratory Supplies, Poole, UK). Cells were then resus-
pended in 300 μl of PBS containing 50 μg/ml propidium
iodide and 0.5 mg/ml RNAse A (Sigma). They were incubated
for 20 minutes in the dark and washed once in PBS/FBS
before analysis on a FACScan flow cytometer. Neutrophils
were incubated overnight with 25 μg/ml etoposide (Sigma) as
a positive control for apoptosis. There were no differences in
the apoptotic state of isolated leukocytes.
Generation of F(ab')2–biotin conjugates
Digestion of anti-FcγRII (iv.3) was completed with the Immu-
noPure® F(ab')2/Fab Ficin kit (Pierce, Rockford, IL, USA). This
was found to have a greater percentage yield than pepsin
digestion in preliminary studies, with no loss of avidity. Bioti-
nylation of F(ab')2 was completed with a Sulfo-NHS-LC-Biotin
kit (Pierce). Efficacy of biotinylation was assessed with the 4-
hydroxyazobenzene-2-carboxylic acid (HABA) assay. To
ensure that the affinity of the antibodies for the receptors was
not compromised in any way after these series of procedures,
an extracellular flow-cytometric staining assay was used to
confirm binding. The biotinylation procedure was also
assessed with streptavidin–phycoerythrin.
Determination of reactive oxygen species
Oxidative burst was measured in neutrophils with the fluoro-
chrome dihydrorhodamine (DHR)-123 (Sigma). This non-fluo-
rescent and cell-permeable probe localises to the
mitochondria, where it is converted into cationic DHR-123. It
detects superoxide by reacting with hydrogen peroxide and/or
peroxynitrite [42,43] to emit a 515 nm fluorescent signal when
excited by a 488 nm argon-ion laser. DHR-123 was dissolved
in dimethylsulphoxide to a concentration of 29 mM and stored
in aliquots at -70°C. Neutrophils were isolated from peripheral
blood by Ficoll–Histopaque density gradient centrifugation.
Heparinised blood was mixed 1:1 with prewarmed RPMI 1640
and layered on a previously prepared step separation medium
of equal volumes of Histopaque 1077 and Histopaque 1119
(Sigma). After centrifugation at 400 g for 30 minutes, the neu-
trophil layer at the 1119 and 1077 interface was carefully
removed. Neutrophils were further purified by hypertonic lysis.
The cell pellet was resuspended in ice-cold sterile water for 20
seconds followed by an equal volume of double-strength PBS
to restore tonicity. They were resuspended to a final concen-
tration of 5 × 106 cells/ml in 1% BSA/PBS and kept on ice
until stimulation. Aliquots (50 μl) were combined with 200 μl
of buffer consisting of saline (0.15 M) with 5 mM HEPES.
DHR-123 was added to give a final concentration of 1 μM and
the cells were incubated at 37°C for 5 minutes. After incuba-
tion, cells were stimulated with heat-aggregated IgG (HAIgG)
(100 μg/ml) or by heterotypic or homotypic cross-linking of
FcγRIIa and/or FcγRIIIb. Cross-linking was achieved by initial
incubation of iv.3-B or 3g8-B (5 μg/ml) at 37°C for 5 minutes,
as described by Vossebeld and colleagues [44] followed by
various timed incubations with (Goat anti-mouse IgG (GAM);
50 μg/ml) or streptavidin (10 μg/ml). HAIgG was prepared by
heating 1 mg/ml IgG in PBS at 63°C for 30 minutes, followed
by centrifugation and aspiration of the supernatant. Preliminary
experiments provided optimum concentrations of iv.3-B, 3g8-
B, GAM, streptavidin and HAIgG to cause activation. In addi-
tion, the time of incubation was also determined. After incuba-
tion, reactions were stopped with a final concentration of 0.2%
sodium azide; the cells were then placed on ice and analysed
immediately by flow cytometry.Available online http://arthritis-research.com/content/9/2/R29
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Statistical analyses
Results are expressed as the arithmetic mean ± SEM for a
given number of values n. Significant differences are defined
is represented by a probability value, p < 0.05. Data was ana-
lysed with a Kolmogorov–Smirnov test for deviations from
Gaussian distributions. All values were less than 0.2, p > 0.1;
all data were therefore assumed to be normally distributed.
Correlation was determined with linear regression to deter-
mine the line of best fit and with a two-tailed Pearson product
moment correlation test to quantify how well x and y varied
together. Statistical differences between two populations
were analysed with either an unpaired t-test for data analysed
for Gaussian distribution, or a two-tailed Mann–Whitney test
for unpaired observations in all other cases. Kinetic distribu-
tions were analysed with either one-way or two-way analysis of
variance with repeated measures. Significant changes (p <
0.05) were then analysed with the Bonferroni Dunn post hoc
test that analyses associations between every combination of
two parameters within the data. Analyses were completed with
GraphPad Prism (version 3.00 for Windows; GraphPad Soft-
ware, San Diego CA, USA) and Statview (version 5.0.1 for
Windows; SAS Institute Inc., Cary, NC, USA). Gene fre-
quency was determined with the Hardy–Weinburg formula.
Results
Surface expression of Fcγ receptors on peripheral 
leucocytes
Expression of FcγRIII
Analysis of receptor expression of basal peripheral leucocytes
determined no significant difference between neutrophil
FcγRIIIb expression in RA and control subjects (p > 0.05; Fig-
ure 1a). About 30% of monocytes expressed detectable levels
of FcγRIIIa, detectable by the 3g8 antibody. There was no sig-
nificant difference between either the level of expression (Fig-
ure 1a) or the percentage of cells expressing FcγRIIIa in the
RA population in comparison with the control (data not
shown); 10% of lymphocytes expressed FcγRIII. These were
either natural killer cells or a T-lymphocyte subset. There was
no difference in expression of FcγRIII in the overall lymphocyte
population (Figure 1a). The gene frequency of NA1 and NA2
distribution in the sample population was comparable to that
of European countries, white and black Americans and Tuni-
sians (Table 2) [45-49]. The distributions of FcγRIIIb allotypes
were similar in RA cases and controls.
Table 2
FcγRIIIb allotype gene frequency
Population Gene frequency
NA1 NA2
Total 0.36 0.64
Control 0.39 0.61
RA 0.34 0.66
The Hardy–Weinburg formula was used to determine Fcγ receptor 
(FcγR)IIIb NA1 NA2 allotype gene frequency. There was no 
difference in distribution between RA and control populations (p > 
0.05).
Figure 1
Expression of Fcγ receptors by rheumatoid and age/sex-matched control leucocytes Expression of Fcγ receptors by rheumatoid and age/sex-matched control leucocytes. Baseline expression of FcγRIIIb (a) or FcγRIIa (b) in patients 
with rheumatoid arthritis (RA) and in controls. Blood was analysed for the baseline expression of FcγRIII on circulating leucocytes in an RA popula-
tion and compared with a control. FcγRIIa was found to be higher on resting monocytes from patients with RA (p < 0.05; RA, n = 18; control, n = 
18). Each experiment was performed in duplicate. (c) Change in FcγRIIIb expression on neutrophils in response to TNF-α. Two-way analysis of vari-
ance revealed no difference in the modulation of FcγRIIIb between RA and controls after stimulation with TNF-α. Results are expressed as the per-
centage change from the baseline expression (mean ± SE). Each experiment was performed in duplicate. MESF, milliequivalents of soluble 
fluorescein.Arthritis Research & Therapy    Vol 9 No 2    Fairhurst et al.
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Expression of FcγRII
Low levels of the inhibitory receptor FcγRIIb have been deter-
mined in neutrophils [50]. It is not known whether this mole-
cule is expressed on the surface and therefore contributes to
FcγR-mediated signalling. Intact iv.3 antibodies detect trace
amounts of FcγRIIb, but it has never been detected by using
Fab fragments of iv.3, either by flow cytometry or in immuno-
precipitation experiments (Susheela Tridandapani, personal
communication). By using biotinylated iv.3 F(ab')2 fragments,
specific for FcγRIIa, the potential impact of FcγRIIb was
eliminated.
The baseline neutrophil expression of FcγRIIa did not differ
between the two conditions and there was no correlation
between resting receptor expression and any clinical measure-
ment of disease (Figure 1b). However, examination of mono-
cytic FcγRIIa revealed a higher resting expression RA than in
controls (Figure 1b). Interestingly, there were no associations
with any of the clinical disease activity parameters measured,
which implies that the loss of FcγRIIa is not associated with
severity of disease.
Fcγ receptor expression after stimulation
Peripheral whole blood from patients with RA or from control
volunteers was incubated with TNF-α, fMLP or RPMI complete
medium alone, as described in the Materials and methods sec-
tion. Surface expression of FcγRIIIb increased after stimulation
with TNF-α (Figure 1c), with no observable differences
between RA and control samples. These results were identical
to those observed after stimulation with fMLP (data not
shown). In addition, after stimulation with either fMLP or TNF-
α a 20 to 30% increase in surface expression of monocytic
FcγRIIIa occurred, but this was not significantly different from
the value at zero time (data not shown). There was no detect-
able modulation in surface expression of FcγRIIa on peripheral
blood neutrophils or monocytes after stimulation with TNF-α or
fMLP (data not shown).
Measurements of neutrophil and systemic activation
Expression and regulation of L-selectin
Examination of the basal expression of L-selectin on neu-
trophils showed a trend towards lower expression in patients
with RA; however, this marginally failed to reach statistical sig-
nificance (p = 0.07; Figure 2a). Examination of an association
between basal L-selectin expression and ESR in patients with
RA revealed a negative correlation between these variables
(R2 = 0.29, p  < 0.05; Figure 2b). This suggests that the
expression of L-selectin on neutrophils and monocytes
decreases with the severity of the disease [36]. Correlations
with other clinical markers of disease were not evident (data
not shown). Analysis of L-selectin expression on monocytes
revealed no difference between RA and control populations
(Figure 2a). However, correlative analysis of ESR and basal L-
selectin on monocytes revealed a similar trend of negative cor-
relation to that for neutrophils (R2 = 0.29, p = 0.06; Figure 2c).
Between 50 and 80% of naïve and between 50 and 90% of
memory CD3-positive T lymphocyte cells reportedly express
L-selectin [51]. Basal expression of L-selectin did not differ
between the two disease conditions (Figure 2a). Furthermore,
comparisons with clinical blood data revealed no association
of L-selectin expression on lymphocytes with any of the param-
eters measured, including ESR (data not shown).
After stimulation with TNF-α, a rapid decrease in expression of
L-selectin within the first 30 minutes was detected (Figure 2d).
Although receptor cleavage seemed to occur to a greater
extent in RA neutrophils than in controls, this was not signifi-
cant. The response to stimulation with fMLP was essentially
identical to that with TNF-α incubation (data not shown). There
were no statistical differences between stimulators or treat-
ment groups at any time point (p > 0.05). On stimulation with
TNF-α or fMLP, monocytic L-selectin expression was also
shed. There was no observable difference between the RA
and the control response for either treatment. Lymphocytes
did not alter their expression of L-selectin in response to TNF-
α or fMLP in either treatment group (p > 0.05; data not shown)
Expression and regulation of CR3
Basal CR3 expression on neutrophils in patients with RA were
no different from those in controls (Figure 3a). However, anal-
ysis of associations between clinical parameters of disease
activity and basal CR3 expression revealed a trend towards a
positive correlation between CR3 expression and ESR (Figure
3b). Analysis of CR3 expression on monocytes did not identify
differences in baseline expression; neither was there any asso-
ciation with other indices of disease activity (Figure 3a, c, and
data not shown).
In concordance with existing reports, the surface expression of
CR3 on neutrophils increased after stimulation with either
fMLP or TNF-α, but no difference was evident between control
and RA populations (Figure 3c and data not shown). Examina-
tion of the TNF-α or fMLP-induced CR3 receptor upregulation
on monocytes revealed no significant differences between the
RA and control populations (data not shown).
Analysis of reactive oxygen species
Analysis of the intracellular release of ROS was determined
with DHR-123. Purified neutrophils were incubated with DHR-
123 before specific stimulation, and the median fluorescence
intensity was determined. Analysis was completed at the max-
imum detectable fluorescence intensity, which was 45 min-
utes after stimulation. Figure 4 demonstrates the maximal ROS
generation by neutrophils from IgG Fc receptor engagement
with the use of different stimuli, in control and RA subjects.
Specific ligation of either FcγRIIa or FcγRIIIb produced an
observable increase in ROS, although this reached statistical
significance only for FcγRIIa ligation in the control group,
where ROS production was higher after FcγRIIa ligation, in
comparison with FcγRIIIb. Heterologous cross-linking ofAvailable online http://arthritis-research.com/content/9/2/R29
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FcγRIIa and FcγRIIIb induces ROS production to a greater
extent than engagement of either receptor alone (Figure 4).
This is consistent with the current data demonstrating that het-
erotypic FcγRIIIb–FcγRIIa co-ligation produces enhanced neu-
trophil activation in terms of phagocytosis, oxidative burst and
release of granular enzymes [44,52]. In addition, HAIgG has
maximal efficiency in producing ROS. This is probably due to
spatial orientation of the HAIgG molecule, which favours clus-
tering of a greater number of receptors on the cell. In these
circumstances, the differential ROS generation between con-
trol and RA groups was not apparent.
Comparisons between the control and RA samples revealed
that the resting generation of ROS by untreated cells was
marginally higher in the RA population than in the controls, but
this was not significant (data not shown). There was no differ-
ence in ROS generation as a result of single FcγR ligation
between the two treatment groups. However, dual ligation of
FcγRIIa and FcγRIIIb resulted in an additive effect in control
populations that was absent from the RA group (p < 0.05,
unpaired t-test). This loss of ROS generation within the RA
group was not correlated with age or with disease severity as
measured by physician-assessed DAS 28 (data not shown).
Furthermore, the sample size was insufficient to determine
effects of gender on loss of ROS generation.
Discussion
We have demonstrated that there is a defect in the coopera-
tive effect of FcγRIIa and FcγRIIIb in mediating ROS
generation in neutrophils. This was not due to a change in
receptor expression, because basal levels of both receptors
were equivalent in control and RA populations, which is con-
sistent with previous reports [51,52]. It is also unlikely that it
results from an aberrant response in the direct downstream
signalling pathways for each individual receptor. Because the
efficacy of HAIgG-induced ROS was not altered, the dispari-
ties must lie in the conformational changes of the receptors
during cross-linking, which results from antigen binding. The
generation of ROS is pivotal in the efficient destruction of for-
eign material [53,54]. The reduction in ROS generation may
therefore account in part for the increased susceptibility and
morbidity associated with infection in RA [27,29,30,53]. How-
ever, the extent of this FcγR-dependent defect is limited
because individuals with FcγRIIIb deficiency do not suffer from
recurrent bacterial infections and because removal of the
FcγRIIIb does not eliminate the phagocytic capacity and sub-
sequent destruction of opsonised bacteria [20,55,56]. We
suggest that, in cases where the pathogenic agonist is less
efficient in the induction of cross-linking, this becomes an
impeding factor in the generation of ROS.
Published data on neutrophil Fc-mediated ROS generation
are conflicting. We demonstrated that the efficacy of ROS
generation by homotypic ligation did not differ between
FcγRIIa and FcγRIIIb, which is consistent with two other stud-
ies [17,38]. This is contrary to the work of Hundt and Schmidt
[37] showing that FcγRIIIb induces a greater oxidative burst
Figure 2
Expression of L-selectin by rheumatoid and age/sex-matched control leucocytes Expression of L-selectin by rheumatoid and age/sex-matched control leucocytes. (a) Baseline expression of L-selectin on peripheral leucocytes in 
patients with rheumatoid arthritis (RA) and control volunteers. Correlation of neutrophil (b) and monocyte (c) L-selectin and erythrocyte sedimenta-
tion rate (ESR). Linear regression of the relationship between resting neutrophil L-selectin expression and the ESR showed a significant correlation. 
Equation statistics are presented in the graph. In addition, Pearson's correlation also confirmed this finding (r = -0.54, p < 0.05; n = 15). Trends 
were also shown between monocyte L-selectin expression and ESR (0.1 > p > 0.05). (d) Neutrophil L-selectin was shed rapidly on TNF-α stimula-
tion. MESF, milliequivalents of soluble fluorescein.Arthritis Research & Therapy    Vol 9 No 2    Fairhurst et al.
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than FcγRIIa. This may be due to the high concentration of
GAM used in their experiments and subsequent non-specific
ligation, particularly because studies with smaller amounts of
GAM do not show this difference in efficacy [38]. In our stud-
ies we generated biotinylated F(ab')2 anti-FcγRIIa and FcγRIIIb
molecules and used streptavidin for cross-linking; the potential
for non-specific ligation of receptors, which can occur when
using a secondary IgG, was therefore eliminated. Initial optimi-
sation studies in the work presented here did not demonstrate
any increase in fluorescence with a concentration twofold
higher for primary or secondary reagents (data not shown).
Furthermore, the concentrations were comparable to those
used in other assays, which activate neutrophils by specific
ligation [15,17,44]. Aside from the controversy about the
relative efficacy of FcγRII and FcγRIIIb in ROS generation,
early studies could not produce an FcγRIIIb-mediated oxida-
tive burst [57,58]. These investigations used a different mon-
oclonal antibody (CBL-FcR-gran-I) against FcγRIIIb in
comparison with all other studies mentioned here (3g8).
Antibodies 3g8 and Gran-1 recognise different epitopes
within the ligand-binding site of FcγRIIIb [59]. This may result
in differences in receptor aggregation, thereby affecting sub-
sequent signalling transduction pathways.
Our analysis of cellular markers of activation, L-selectin and
CR3, also suggest that the neutrophils of patients with RA in
the periphery are activated before joint infiltration.
Furthermore, the negative correlation between neutrophil L-
selectin expression and ESR suggests that neutrophil activa-
tion increases with disease severity. The altered expression in
adhesion molecules may account for the defective migratory
capacity of neutrophils to inflammatory targets observed in
patients with RA [60]. Although several studies have shown
that L-selectin is lower on neutrophils from synovial fluid, there
are fewer observations for neutrophils from peripheral blood.
Three studies report no change; however, Bond and col-
leagues have shown a decreased level of L-selectin on circu-
lating granulocytes [61-64]. Previous studies have also failed
to determine a difference in neutrophil CR3 expression in
peripheral blood in RA in comparison with controls; however,
upregulation is widely reported in synovial neutrophils
[61,63,65]. The disparity in the data probably arises from inter-
patient variability, small sample size, and requirements for
study recruitment, together with the use of cell separation
techniques that downregulate L-selectin and upregulate CR3.
In the studies presented here, neutrophils were stimulated
with an optimum concentration of fMLP or TNF-α to examine
Figure 3
Expression of complement receptor type 3 (CR3) by rheumatoid and age/sex-matched control leucocytes Expression of complement receptor type 3 (CR3) by rheumatoid and age/sex-matched control leucocytes. (a) Baseline expression of CR3 expres-
sion on peripheral leucocytes in Patients with rheumatoid arthritis and control volunteers. Correlation of neutrophil (b) and monocyte (c) CR3 and 
erythrocyte sedimentation rate (ESR). There was a trend for a positive correlation between neutrophil expression and ESR; however, this marginally 
failed to reach statistical significance (p = 0.06). (d) Neutrophil CR3 expression was upregulated in response to TNF-α. MESF, milliequivalents of 
soluble fluorescein.Available online http://arthritis-research.com/content/9/2/R29
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any differences in the shedding response of L-selectin. There
was no difference in L-selectin shedding between RA and
controls. However, further preliminary work has shown that the
loss in receptor expression by TNF-α is dose-dependent and
that neutrophils from patients with RA require a lower concen-
tration of TNF-α for equivalent shedding than do those in con-
trol samples. An earlier study has shown that TNF receptor
expression is equivalent in patients and controls, reducing the
probability that this is a cause of the effect [66].
The studies presented here demonstrate that functional abnor-
malities exist in peripheral neutrophils from patients with RA.
This defect resides in the capacity of neutrophils to generate
ROS in response to cooperative ligation of FcγRIIa and FcγRI-
IIb. The decreased production of ROS is unrelated to the level
of receptor expression. This, together with the altered expres-
sion of adhesion molecules, may account for the increase in
susceptibility and morbidity to bacterial infections that exists in
RA.
Conclusion
This study demonstrates that patients with active RA have an
altered capacity of generating ROS in response to dual liga-
tion of FcγRII and FcγRIIIb. This may be a compensatory mech-
anism to downregulate the response to self ICs, and may
affect the response to bacterial infections.
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